PHARMA

Quarterly rpt on consolidated results for the financial period ended 31/12/2005

Amended Announcements
Please refer to the earlier announcement reference number: PB-060222-65946

PHARMANIAGA BERHAD

Quarterly report for the financial period ended

31/12/2005
Quarter4
Financial Year End31/12/2005
The figureshave been audited

Attachments

pharma_klse0512_final_amended2.doc
397 KB


Remarks :
Amendment was made to the following item for the 4th Quarterly Results, which was announced on 22 February 2006:-

1. Net Asset per share in Item 7 of Part A2 and 12 of Part II respectively.

SUMMARY OF KEY FINANCIAL INFORMATION
31/12/2005


INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR CORRESPONDING QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR CORRESPONDING PERIOD
31/12/2005 
31/12/2004 
31/12/2005 
31/12/2004 
 
 
 
 
RM'000
RM'000
RM'000
RM'000
1Revenue
244,209
200,777
936,431
799,991
2Profit/(loss) before tax
657
22,264
42,072
81,778
3Profit/(loss)
after tax and minority
interest
1,012
13,368
26,902
50,835
4Net profit/(loss) for
the period
1,012
13,368
26,902
50,835
5Basic earnings/(loss) per share (sen)
0.95
13.12
25.98
50.18
6Dividend per share (sen)
3.50
4.50
3.50
4.50



AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR
END
7Net assets per share (RM)

2.9700
2.7900

Note: For full text of the above announcement, please access KLSE Web site at www.klse.com.my


Remarks :
For the current financial year ended 31 December 2005, the Board of Directors recommends a final tax exempt dividend of 11.5% (2004:10.5%) on ordinary share in issue of 106,951,988 (2004:102,289,298 ordinary shares) for shareholders' approval at the forthcoming Annual General Meeting. The date of the Annual General Meeting and the book closure for final exempt dividend payment will be announced in due course.

Announcement Info

Company NamePHARMANIAGA BERHAD  
Stock Name PHARMA    
Date Announced7 Mar 2006  
CategoryFinancial Results
Reference NoPB-060307-64753

View original report